Facilitating Shared Decisionmaking About Prostate Cancer Screening

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00013247
First received: March 14, 2001
Last updated: February 6, 2014
Last verified: February 2007

March 14, 2001
February 6, 2014
Not Provided
Not Provided
Not Provided
  • A 10- item validated knowledge index
  • Responses to questions on CaP natural history, treatment efficacy, PSA accuracy, and expert disagreement about the PSA
  • Whether screening was discussed with provider
  • Scores on decision information seeking, participation and satisfaction scales
  • Screening and treatment preferences
  • PSA testing rates
Complete list of historical versions of study NCT00013247 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Facilitating Shared Decisionmaking About Prostate Cancer Screening
Facilitating Shared Decisionmaking About Prostate Cancer Screening

Due to the disputed efficacy of prostate cancer (CaP) screening and treatment, most authorities recommend that providers inform and involve patients in CaP screening decisions.

Background:

Due to the disputed efficacy of prostate cancer (CaP) screening and treatment, most authorities recommend that providers inform and involve patients in CaP screening decisions.

Objectives:

This study evaluated two interventions designed to facilitate this process.

Methods:

1152 male veterans age 50+ with no CaP and primary care appointments at four VA medical facilities in VISN 23 were randomly assigned to one of three groups: mailed pamphlet intervention, mailed video intervention, or usual care (control). Intervention materials were mailed two weeks prior to a target primary care appointment and patient telephone surveys were conducted one week (T1) and one year (T2) after the target appointment. Outcomes included: a 10- item validated knowledge index; responses to questions on CaP natural history, treatment efficacy, PSA accuracy, and expert disagreement about the PSA; whether screening was discussed with provider; scores on decision information seeking, participation and satisfaction scales; screening and treatment preferences; and PSA testing rates.

Status:

Complete

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Prostate Cancer
Behavioral: Prostate Cancer Screening Education
Arm 1
Intervention: Behavioral: Prostate Cancer Screening Education

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1152
December 2002
Not Provided

Inclusion Criteria:

Patients must be male veterans, age 50 and older, with a scheduled primary care appointment at one of 5 VISN 13 medical facilities. Patients diagnosed with prostate cancer will be excluded.

Exclusion Criteria:

Male
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00013247
IIR 99-277
No
Department of Veterans Affairs
Department of Veterans Affairs
Not Provided
Principal Investigator: Melissa R. Partin, PhD Minneapolis VA Health Care System
Department of Veterans Affairs
February 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP